Zafgen Obesity Drug Trial on Hold After Patient Deaths

  • Company says patient died of blood blockages in the lungs
  • U.S. Food and Drug Administration stops trial from continuing

Zafgen Inc. said its trial of an experimental drug to fight obesity was placed on hold by U.S. regulators after a second patient died.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.